Interviews

Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each. 

After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.

The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.

Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.

Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.

While Democrat politicians - and most voters- want to see drug pricing negotiations introduced in the US for the first time, pharma leaders believe a deal on out of pocket costs will be agreed instead.

BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.

As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.

While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.

In this video fireside chat from the recent BIO-Europe Digital 2021 conference, the CEO of Institut Pasteur Korea outlines the research institute's role in managing the COVID-19 situation in the country, progress with the COVID-19 pipeline, issues related to the development of drugs and vaccines for the pandemic in South Korea, and her goals for the institute over the next few years.

SciNeuro’s latest in-licensing deals include three assets for major neurodegenerative diseases from Lilly and Mabylon, but the Chinese bioventure is looking beyond the shopping spree at what it sees as outstanding CNS needs.

After being selected as an awardee of J&J’s Innovation QuickFire Challenge On Neuroscience in June, Korean bioventure BIORCHESTRA has been attracting attention from the global neuroscience community. CEO Branden Ryu talks to Scrip what makes its technology unique and how it aims to meet major unmet needs in RNA therapeutics and neurodegenerative disorders.